Results 21 to 30 of about 8,184 (204)

Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin

Drugs in Context, 2013
For patients with type 2 diabetes mellitus, management of hyperglycemia is typically complex, and few patients successfully achieve and maintain recommended targets for glycated hemoglobin (HbA1c).
Jeffrey Freeman
doaj   +1 more source

Mild Biamidine-Transfer Conditions for the Synthesis of Aliphatic Biguanides

SynOpen, 2021
This study focuses on the development of new synthetic pathways to monosubstituted biguanides from amines. An exhaustive comparison of the conditions and reagents used for biamidine transfer was performed.
Rostyslav Bardovskyi, Marie Fabre, Cyril Ronco, Rachid Benhida   +3 more
doaj   +1 more source

Mechanisms of NMDA Receptor Inhibition by Biguanide Compounds

Pharmaceuticals
N-methyl-D-aspartate (NMDA) receptors are inhibited by many medicinal drugs. The recent successful repurposing of NMDA receptor antagonists ketamine and dextromethorphan for the treatment of major depressive disorder further enhanced the interest in this
Arseniy S. Zhigulin, Anastasiya O. Novikova, Oleg I. Barygin   +2 more
doaj   +1 more source

The Pituitary Gland is a Novel Major Site of Action of Metformin in Non-Human Primates: a Potential Path to Expand and Integrate Its Metabolic Actions

Cellular Physiology and Biochemistry, 2018
Background/Aims: Biguanides are anti-hyperglycaemic agents used to treat diabetes by acting primarily on the liver, inhibiting hepatic gluconeogenesis. However, biguanides may target other key metabolic tissues to exert beneficial actions. As the “master
Mari C. Vázquez-Borrego, Antonio C. Fuentes-Fayos, Manuel D. Gahete, Justo P. Castaño, Rhonda D. Kineman, Raúl M. Luque   +5 more
doaj   +1 more source

Designed Lewis Acid–Base Passivation for High Performance Perovskite Solar Cells

Advanced Functional Materials, EarlyView.
ABSTRACT Silicon's high cost and long energy payback time remain major barriers to the global expansion of solar power. In contrast, metal–halide perovskites offer abundant, solution‐processable absorbers, and have achieved efficiencies of 25%–30%, positioning them as strong competitors to silicon.
Afna Manaf, Hiba Shahulhameed, Bhabani Sankar Swain, Shengzhong (Frank) Liu, Adel Najar   +4 more
wiley   +1 more source

Human Leukocyte Elastase Triggered Nanoparticles for Targeted Antimicrobial Delivery and Oral Microbial Modulation

Advanced NanoBiomed Research, EarlyView.
This study explores enzyme‐responsive nanoparticles for targeted antimicrobial release in inflamed oral environments. Nanoparticles formed by complexing peptides and chlorhexidine respond to human leukocyte elastase and release chlorhexidine selectively. P7 (ECAAPVCE)‐based formulations show optimal properties and stability, with antimicrobial activity
Mohammed A. Hadis, Ignacio Insua, Farah N. S. Raja, Álvaro Vila, William M. Palin, Michael R. Milward, Paul R. Cooper, Sarah A. Kuehne, Owen Addison, Paco Fernandez‐Trillo   +9 more
wiley   +1 more source

Target engagement of biguanides in colorectal carcinoma

Discover Chemistry
Colorectal cancer (CRC) continues to be the largest reason for disease-related illnesses and fatalities globally, emphasizing the critical necessity finding new along with affordable therapy approaches.
Poulami Patra, Rajat Subhra Dutta, Supriya Sahu   +2 more
doaj   +1 more source

Metformin: Focus on Melanoma

Frontiers in Endocrinology, 2018
Metformin is the most common biguanide used in the treatment of diabetes, with 120 million treated patients worldwide. Metformin decreases hyperglycemia without inducing hypoglycemia in diabetic patients and is very well tolerated.
Emilie Jaune, Emilie Jaune, Stéphane Rocchi, Stéphane Rocchi   +3 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Recent Developments in Diabetes Management: Exploring Receptors, Pathways, and Compounds

BIO Integration
Diabetes mellitus (DM) is a widespread metabolic disorder with profound effects on vital organs. Often referred to as a “systemic” or “multi-organ” disorder due to the impact on key organs, such as the kidneys, pancreas, eyes, and heart, DM is ...
Pallavi Pandey, Vikash Jakhmola, Supriyo Saha, Anand Gaurav   +3 more
doaj   +1 more source